Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China

publication date: Jun 2, 2023

Beijing CANbridge Pharma was approved to launch Maralixibat Chloride Oral Solution (Livmarli®) in China to treat cholestatic pruritus in patients at least one year old with Alagille syndrome. Livmarli (maralixibat) inhibits ileal bile acid transporters (IBAT), blocking bile circulation and lowering bile acid levels in the liver and serum. This reduces liver injury and relieves pruritus. Livmarli is the only medication approved in China, the US and EU to treat Alagille syndrome cholestatic pruritus. CANbridge, a rare disease company, acquired China rights for Livmarli from Mirum Pharma, a San Francisco-area biopharma. More details....

Stock Symbol: (HK: 1228)

Share this with colleagues: